Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Chinese Adults with Paroxysmal Nocturnal Hemoglobinuria
ChiCTR2400088580Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Peking Union Medical College Hospital. Primary endpoint: Percentage change of LDH from baseline on Day 183 (Week 26). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on ChiCTR2400088580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088580.